Amarin Co. plc (NASDAQ:AMRN) has been given an average rating of “Buy” by the eighteen research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $13.54.
A number of research analysts recently issued reports on the stock. Piper Sandler assumed coverage on shares of Amarin in a research report on Tuesday, August 25th. They set an “overweight” rating and a $21.00 target price for the company. Cantor Fitzgerald decreased their price objective on shares of Amarin from $35.00 to $15.00 in a research report on Tuesday, September 8th. BidaskClub downgraded shares of Amarin from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 30th. HC Wainwright restated a “buy” rating on shares of Amarin in a research report on Wednesday, August 5th. Finally, Stifel Nicolaus reduced their price target on shares of Amarin from $8.00 to $5.00 and set a “hold” rating for the company in a research report on Thursday, September 3rd.
Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Amarin in the 1st quarter worth approximately $43,000. AE Wealth Management LLC raised its holdings in shares of Amarin by 217.0% in the 1st quarter. AE Wealth Management LLC now owns 40,591 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 27,788 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Amarin by 10.5% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 46,233 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 4,400 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Amarin by 152.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 49,199 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 29,740 shares in the last quarter. Finally, Trexquant Investment LP raised its holdings in shares of Amarin by 137.8% in the 1st quarter. Trexquant Investment LP now owns 338,476 shares of the biopharmaceutical company’s stock valued at $1,354,000 after purchasing an additional 196,120 shares in the last quarter. 42.14% of the stock is owned by institutional investors and hedge funds.
Shares of AMRN opened at $4.18 on Thursday. The firm has a market capitalization of $1.65 billion, a PE ratio of -104.50 and a beta of 2.65. Amarin has a 1-year low of $3.95 and a 1-year high of $26.12. The company’s fifty day moving average price is $6.22 and its 200-day moving average price is $7.71.
Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. The firm had revenue of $133.72 million for the quarter, compared to analyst estimates of $149.48 million. Amarin had a negative net margin of 2.30% and a negative return on equity of 2.16%. The business’s quarterly revenue was up 33.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.02 earnings per share. On average, equities research analysts forecast that Amarin will post -0.02 EPS for the current fiscal year.
Amarin Company Profile
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Featured Story: What is Liquidity?
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.